HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Reznikoff, G. Articles by Rainbow, T. C. Search for Related Content PubMed PubMed Citation Articles by Reznikoff, G. Articles by Rainbow, T. C.

Similar distribution of monoamine oxidase (MAO) and parkinsonian toxin (MPTP) binding sites in human brain

From the Departments of Pharmacology (Drs. Reznikoff, Parsons, and Rainhow) and Biology (Dr. Manaker), and the Division of Neuropathology (Dr. Rhodes), School of Medicine, University of Pennsylvania, Philadelphia, PA.

1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) causes parkinsonism in humans and other species. We found [³H] MPTP binding sites that were saturable, specific, and of high affinity. In autoradiographic studies, the highest binding densities of [³H] MPTP occurred in the hypothalamus, interpeduncular nucleus, and ependymal lining of the ventricles. High to moderate binding was seen in the dentate gyrus, caudate, put0amen, substantia nigra, and cingulate cortex. The distribution of [³H] MPTP binding correlated with the distribution of [³H] pargyline binding to MAO. Human substantia nigra contains more MPTP binding sites than rat substantia nigra, and this may explain the sensitivity of humans to the neurotoxic effects of MPTP.

Address correspondence and reprint requests to Dr. Reznikotf Department of Pharrnacology /G3. School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.

This work was supported by NIH grants NS19597 and NS20006, Esther A. and Joseph Klingenstein and Alfred P. Sloan fellowships to TCR, the United Parkinson Fund, and NIH Biomedical Research Support Grants to the University of Pennsylvania. B.P. was a Lieberman fellow. S.M. was supported hy Medical Scientist Training Program NIH 5T32 GM 07170, and C.H.R. was supported in part by 2T32 NS07064. T.C.R. was an Established Investigator of the American Heart Association.

Accepted lor publication January 14, 1985.